https://twitter.com/renalandurology/status/1725249636313477324Patients with both cancer and diabetes who take sodium glucose cotransporter 2 inhibitors (SGLT2i) rather than glucagon-like peptide 1 receptor agonists (GLP-1 RA) have higher rates of certain adverse events, investigators reported at #KidneyWk. https://bit.ly/3G7U02w
— Renal & Urology News (@renalandurology) Nov 16, 2023
Thursday, November 16, 2023
@renalandurology
http://twitter.com/renalandurology
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment